Edition:
India

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

39.72USD
1:30am IST
Change (% chg)

$-0.46 (-1.14%)
Prev Close
$40.18
Open
$40.08
Day's High
$40.40
Day's Low
$39.59
Volume
227,486
Avg. Vol
126,967
52-wk High
$43.29
52-wk Low
$19.00

Latest Key Developments (Source: Significant Developments)

Xencor Reports Q1 Loss Per Share $0.62
Tuesday, 8 May 2018 

May 7 (Reuters) - Xencor Inc ::XENCOR REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.62.Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S.EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO 2023.EXPECTS TO END 2018 WITH APPROXIMATELY $500 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.  Full Article

Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Xencor Inc ::XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS.XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018.  Full Article

Xencor posts Q3 loss of $0.33 per share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Xencor Inc :Xencor reports third quarter 2017 financial results and provides clinical pipeline update.Q3 revenue $7.1 million versus i/b/e/s view $6.3 million.Q3 loss per share $0.33.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Xencor q2 earnings per share $1.13
Wednesday, 3 Aug 2016 

Xencor Inc : Q2 earnings per share $1.13 .Q2 revenue $66 million versus $1.0 million.  Full Article

Xencor provides updates on lead programs, reviews bispecific oncology partnership
Tuesday, 28 Jun 2016 

Xencor Inc : Xencor provides updates on lead programs and reviews bispecific oncology partnership; announces expansion of bispecific oncology pipeline at analyst day . Announced expansion of its pipeline with two new bispecific oncology programs .Remain on track to initiate Phase 1 trials with subcutaneous formulations of both XMAB5871 and XMAB7195 this year.  Full Article

Xencor enteres into collaboration and license agreement with Novartis
Tuesday, 28 Jun 2016 

Xencor Inc : Xencor announces strategic collaboration for bispecific programs, including XMAB 14045 and XMAB 13676 . Has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics . Parties will collaborate and share development costs for worldwide development of XMAB14045 and XMAB13676, with Xencor . Will receive a $150 million upfront payment and is eligible to receive clinical, regulatory and sales milestone payments for successful programs . Says eligible to receive tiered, low double-digit royalties for sales of XMAB14045 and XMAB13676 outside of U.S. . Novartis to receive worldwide rights to co's bispecific technology to develop and commercialize four additional targets selected by Novartis .Says Novartis will receive a worldwide non-exclusive license to use Xencor's XMAB FC technologies in up to ten molecules.  Full Article

BRIEF-Xencor Reports Q1 Loss Per Share $0.62

* Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S